The Global Alzheimer’s Platform Foundation® (GAP) has successfully compiled a biospecimen database with comprehensive participant representation across cognition, ethnicity, and race—ensuring your research reflects the populations it’s meant to serve. These were collected from volunteers in two GAP-sponsored studies: Bio-Hermes-001 and Apheleia-001. This unique repository of biological specimens offers an unprecedented opportunity to advance Alzheimer’s disease, and can be made available to you through our online portal.

Biospecimen Aliquots

This premier collection represents the most comprehensive and clinically validated biorepository featuring multiple aliquots of highly annotated Whole Blood and plasma samples clinically collected from study volunteers. These biospecimens include people from traditionally understudied populationswho are either cognitively normal, have mild cognitive impairment (MCI) or have an Alzheimer’s Disease (AD) diagnosis.

Comprehensive & High Quality Biospecimens

Bio-Hermes-001 and Apheleia-001 biospecimens adhere to ICH-E14 GCP standards, and maintain full IRB approval with a streamlined environment to gain access to the samples. Every biospecimen follows strict collection and processing protocols, as outlined in our comprehensive lab manual, ensuring no freeze-thaw cycles and continuous storage at -80°C. The Bio-Hermes-001 biospecimens have been used in supporting FDA clearance for the first blood-based biomarker test as well as many validation tests for industry leading diagnostic companies. The aliquots include rich clinical data, demographics, blood biomarker and Aβ PET scan results.

In-Practice & Best Usages

Diagnostics:

Early-stage development can be accelerated by using the same biospecimens that have established readouts from peer-based testing testing. Team can also interrogate performance in the intermediate zone and concentrate on a specific sample type. Additionally, GAP can organize defined sample cohorts—such as low, mid, and high—for use in low limit detection assays. GAP provides the tools to plot and review receiver operating characteristic (ROC) curves.

Early Researchers:

Often, researchers and scientists are seeking biospecimens to complete their cohort. These are typically clinically annotated but have limited biomarker data. GAP can offer biospecimens to support these efforts, especially when PET/CT data isn’t available. Depending on your research focus, GAP can also curate specific cohorts tailored to your biomarker requirements.

GAP's
biospecimen repository...

Most extensively characterized biospecimens of cognitively normal, MCI, and Mild AD cohorts in Alzheimer’s disease to date

Over 100,000+ aliquots ready to ship

Highly annotated Whole Blood and plasma samples

Bulk pricing and incentives considered for larger orders

Frequently Asked
Questions

Bio-Hermes-001 and Apheleia-001 sample sets are complete, as those studies have ended, and GAP will not be adding additonal biospecimens until/unless more studies are added to the repository. The inventory listing is updated as biospecimens are reserved/shipped.

GAP can provide inventory upon request based on your needs. Once your request has been approved and payment has been received, the biospecimens are reserved and then promptly shipped.

GAP is interested in improving the research environment. Pricing incentives can be considered for larger orders.

Contact

Tim Keefe

Global Alzheimer’s Platform Foundation

(978) 621-7349

TKeefe@globalalzplatform.org

    To top